Testing effectiveness (Phase 2)Study completedNCT02028364What this trial is testingPet Imaging as a Biomarker in Hormone Refractory postmenopausaL WomenWho this might be right forBreast Cancer Jules Bordet Institute 55
Testing effectiveness (Phase 2)Not Yet RecruitingNCT07102940What this trial is testingEfti in Patients With Hormone Receptor Positive/HER2-neg Breast CancerWho this might be right forBreast CancerHER 2 Negative Breast CancerHR Positive/HER-2 Negative Breast Cancer+1 more George Washington University 50
Testing effectiveness (Phase 2)Looking for participantsNCT05868226What this trial is testingPRE-ISPY Phase I/II Oncology Platform ProgramWho this might be right forHER2-positive Breast CancerMetastatic CancerMetastatic Breast Cancer+29 more QuantumLeap Healthcare Collaborative 280
Not applicableNot Yet RecruitingNCT05980208What this trial is testingA Real-world Study of Inetetamab for First-line Treatment of MBCWho this might be right forBreast CancerReal-world Study Hunan Cancer Hospital 150
Early research (Phase 1)Ended earlyNCT06878248What this trial is testingAssess CLBR001+ABBV-461 in Subjects With Locally Advanced or Metastatic Breast CancerWho this might be right forBreast Cancer MetastaticLocally Advanced Breast Cancer (LABC)Malignant Neoplasm of Breast+3 more Calibr, a division of Scripps Research 10
Testing effectiveness (Phase 2)Study completedNCT00796978What this trial is testingTrastuzumab in Treating Older Women With Early-Stage Breast CancerWho this might be right forBreast Cancer Cynthia Owusu, MD 56
Early research (Phase 1)Study completedNCT03251378What this trial is testingA Multi-Center, Open-Label Study of Fruquintinib in Solid Tumors and Colorectal, and Breast CancersWho this might be right forAdvanced Solid TumorsMetastatic Colon CancerMetastatic Breast Cancer+4 more Hutchison Medipharma Limited 129
Large-scale testing (Phase 3)Study completedNCT03262935What this trial is testingSYD985 vs. Physician's Choice in Participants With HER2-positive Locally Advanced or Metastatic Breast CancerWho this might be right forMetastatic Breast Cancer Byondis B.V. 437
Testing effectiveness (Phase 2)Ended earlyNCT04862143What this trial is testingPilot Decentralized Clinical Trial in Men and Pre and Post-menopausal Women With Breast Cancer and a Specific Mutation (PIK3CA) Treated With Alpelisib in Combination With FulvestrantWho this might be right forAdvanced Breast Cancer Novartis Pharmaceuticals 2
Early research (Phase 1)Active Not RecruitingNCT04692831What this trial is testingTesting a New Imaging Agent to Identify CancerWho this might be right forHER-2 Positive Malignant Carcinoma of BreastHER-2 Protein OverexpressionHER2-positive Metastatic Breast Cancer Memorial Sloan Kettering Cancer Center 60
Testing effectiveness (Phase 2)Ended earlyNCT01934894What this trial is testingCabazitaxel Plus Lapatinib as Therapy for HER2-Positive Metastatic Breast Cancer Patients With Intracranial MetastasesWho this might be right forMetastatic Breast Cancer With Intracranial Metastases SCRI Development Innovations, LLC 11
Testing effectiveness (Phase 2)Ended earlyNCT03931551What this trial is testingOlaparib+Trastuzumab in HER2[+],Breast Cancer Susceptibility Gene (BRCA) Mutated Advanced Breast CancerWho this might be right forAdvanced Breast Cancer MedSIR 5
Testing effectiveness (Phase 2)Looking for participantsNCT05704829What this trial is testingNeoAdjuvant Therapy With Trastuzumab-deruxtecan Versus Chemotherapy+Trastuzumab+Pertuzumab in HER2+ Early Breast CancerWho this might be right forHER2-positive Early Breast Cancer Women's Cancer Study Group GmbH 702
Large-scale testing (Phase 3)Study completedNCT01547741What this trial is testingDocetaxel and Cyclophosphamide Compared to Anthracycline-Based Chemotherapy in Treating Women With HER2-Negative Breast CancerWho this might be right forBreast Cancer NSABP Foundation Inc 4,242
Early research (Phase 1)Ended earlyNCT01238029What this trial is testingDose Finding Study for Combination of Capecitabine, Lapatinib and Vinorelbine in Metastatic Breast CancerWho this might be right forMetastatic Breast CancerHER2 PositiveFirst or Second Line Therapy+1 more Sponsor GmbH 12
Large-scale testing (Phase 3)UnknownNCT03863223What this trial is testingPyrotinib in Combination With Trastuzumab and Docetaxel in Patients With HER2 Metastatic Breast CancerWho this might be right forMetastatic Breast Cancer Jiangsu HengRui Medicine Co., Ltd. 590
Testing effectiveness (Phase 2)Looking for participantsNCT04923542What this trial is testingSRS & Abemaciclib w/wo Imlunestrant in the Management of HR+/HER2- Breast CA Brain MetastasesWho this might be right forBrain MetastasesHR+ Metastatic Breast Cancer H. Lee Moffitt Cancer Center and Research Institute 31
Post-approval studies (Phase 4)UnknownNCT02089854What this trial is testingAdjuvant Endocrine Therapy for Estrogen Receptor-beta Positive Triple Negative Breast CancerWho this might be right forFemale Breast Cancer Peking Union Medical College Hospital 800
Large-scale testing (Phase 3)Study completedNCT00288002What this trial is testingCombination Chemotherapy With or Without Capecitabine and/or Trastuzumab Before Surgery in Treating Women With Stage I, Stage II, or Stage III Breast CancerWho this might be right forBreast Cancer GBG Forschungs GmbH 1,500
Not applicableActive Not RecruitingNCT07692230What this trial is testingMRI-Driven Precision Typing and Response Prediction in Luminal Breast CancerWho this might be right forHR Positive/HER-2 Negative Breast Cancer Fudan University 2,000